RGLS - Wutah pendapatan taun lumaku Regulus Therapeutics

Production diversification through external contractors impacts the revenue trend over the last four quarters year-over-year, where the parameter value is 0.00. The scientific authority of Regulus Therapeutics (RGLS) in miRNA therapy for polycystic kidney disease strengthens the position of RGLS. However, fierce competition in the rare disease market and the risk of clinical trial failure create pressure on the stock price, as this chart clearly demonstrates.

For a biotech sector investor, Regulus Therapeutics (RGLS) positions are determined by the company's ability to monetize innovations in miRNA therapy for the treatment of polycystic kidney disease. The current value of 0.00 reflects the percentage change in revenue over the last twelve months compared to the previous year, where the year-over-year product sales volume dynamics for the TTM allow for the filtering of speculative noise and confirm the fundamental stability of the business.